The Cypriot Research Promotion Foundation (RPF) selected for funding the project “HEPATOMICS”, aimed to identify novel peripheral blood biomarkers for liver damage in b-thalassaemia through the use of “omics” technologies. β-thalassaemia is a hereditary haemoglobinopathy caused by reduced or absent expression of β-globin. In its most serious form, it leads to severe anaemia and related complications in major organs. Unless treated, it results in childhood death. In the overwhelming majority of patients, treatment is symptomatic rather than curative and involves regular blood transfusions and iron chelation therapy. This project, started in 2019, aims primarily to identify potential non-invasive, novel serum diagnostic biomarkers for different stages of liver disease (fibrosis and cirrhosis) in β-thalassaemia patients using combined data from proteomics, metabolomics and transcriptomics. Apart from CVBF, the project, lasting two years, foresees the involvement of The Cyprus Institute of Neurology and Genetics (CING), coordinator of the project, the Cypriot Ministry of Health and The Royal London Hospital (UK). CVBF will provide its contribution in the investigation of regulatory issues on the management of ‘omics’ data.

About the Author: maria


By Published On: March 26th, 2020Categories: News0 Comments